Should I buy or sell POINT Biopharma Global stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PNT, but not buy additional shares or sell existing shares. View PNT analyst ratings or view top-rated stocks .

What is POINT Biopharma Global's stock price target for 2024?

10 analysts have issued 1-year price targets for POINT Biopharma Global's stock. Their PNT share price targets range from $12.50 to $14.00. On average, they anticipate the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 2.4% from the stock's current price. View analysts price targets for PNT or view top-rated stocks among Wall Street analysts .

How were POINT Biopharma Global's earnings last quarter?

POINT Biopharma Global Inc. (NASDAQ:PNT) released its earnings results on Monday, November, 13th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.07. The business earned $2.79 million during the quarter, compared to analyst estimates of $8 million. POINT Biopharma Global had a trailing twelve-month return on equity of 21.10% and a net margin of 39.62%.

NASDAQ:PNT

POINT Biopharma Global (PNT) Stock Price, News & Analysis

→ Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad)

Free PNT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $12.49
▼
$12.51
50-Day Range: $12.45
▼
$14.23
52-Week Range: $6.57
▼
$14.35

Volume: 3.29 million shs
Average Volume: 1.44 million shs
Market Capitalization: $1.33 billion

P/E Ratio: 13.89
Dividend Yield: N/A
Price Target: $12.80

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media

Get POINT Biopharma Global alerts:

POINT Biopharma Global MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 2.4% Upside
$12.80 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.69) to ($0.68) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.21 out of 5 stars

Medical Sector

896th out of 913 stocks

Pharmaceutical Preparations Industry

393rd out of 402 stocks

1.0

Analyst's Opinion

Consensus Rating
POINT Biopharma Global has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 10 hold ratings, and no sell ratings.
Amount of Analyst Coverage
POINT Biopharma Global has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for PNT.

0.0

Dividend Strength

Dividend Yield
POINT Biopharma Global does not currently pay a dividend.
Dividend Growth
POINT Biopharma Global does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PNT.

0.6

News and Social Media Coverage

Search Interest
1 people have searched for PNT on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, POINT Biopharma Global insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.00% of the stock of POINT Biopharma Global is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
59.53% of the stock of POINT Biopharma Global is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for POINT Biopharma Global are expected to grow in the coming year, from ($0.69) to ($0.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of POINT Biopharma Global is 13.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.89.
Price to Earnings Ratio vs. Sector
The P/E ratio of POINT Biopharma Global is 13.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 265.05.
Price to Book Value per Share Ratio
POINT Biopharma Global has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Timothy Sykes

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

About POINT Biopharma Global Stock (NASDAQ:PNT)

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

Ad Timothy Sykes

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

PNT Stock News Headlines

April 8, 2024 | bloomberg.com

Investing in biopharma innovation: Can you stay one step ahead?

January 8, 2024 | businesswire.com

Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company

April 18, 2024 | Timothy Sykes (Ad)

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

December 27, 2023 | finance.yahoo.com

Lilly Completes Acquisition of POINT Biopharma

December 22, 2023 | markets.businessinsider.com

POINT Biopharma Global Rating Adjustment: Hold Recommendation Following Shareholder Dynamics and Acquisition Prospects

December 22, 2023 | msn.com

Brookline Capital Downgrades POINT Biopharma Global (PNT)

December 22, 2023 | benzinga.com

POINT Biopharma Global Stock (NASDAQ:PNT), Guidance and Forecast

December 18, 2023 | msn.com

Lilly extends tender offer for POINT Biopharma to Dec. 22

April 18, 2024 | Timothy Sykes (Ad)

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

December 18, 2023 | seekingalpha.com

Why POINT Biopharma Global Is At Least A Hold On Disappointing Readout

December 18, 2023 | markets.businessinsider.com

Lantheus Holdings And POINT Biopharma Announced Lu-PNT2002 Phase 3 SPLASH Study Results

December 8, 2023 | msn.com

POINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should Know

December 4, 2023 | markets.businessinsider.com

Lilly Says Tender Offer Expiration Extended Related To POINT Biopharma Acquisition

November 30, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Regeneron (REGN) and Incyte (INCY)

November 17, 2023 | markets.businessinsider.com

Hold Rating on POINT Biopharma Global: An Assessment of Acquisition Offer, Pipeline Updates, and Financial Stability

November 17, 2023 | finance.yahoo.com

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023

November 15, 2023 | benzinga.com

POINT Biopharma Global Stock (NASDAQ:PNT) Earnings Dates and Earning Calls

November 15, 2023 | markets.businessinsider.com

Lilly Receives NRC Consent In Connection With Proposed Acquisition Of POINT Biopharma

November 15, 2023 | markets.businessinsider.com

Piper Sandler Keeps Their Hold Rating on POINT Biopharma Global (PNT)

November 14, 2023 | benzinga.com

POINT Biopharma Global (PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price?

November 14, 2023 | seekingalpha.com

POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge

November 13, 2023 | benzinga.com

Recap: POINT Biopharma Global Q3 Earnings

November 13, 2023 | markets.businessinsider.com

POINT Biopharma Reports Loss In Q3, Flat With Last Year, A Week After Lilly Agreed To Acquire It

November 13, 2023 | finance.yahoo.com

POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

November 8, 2023 | msn.com

Eli Lilly extends expiration of tender offer to acquire Point Biopharma

November 8, 2023 | markets.businessinsider.com

Lilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16

November 8, 2023 | finance.yahoo.com

Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma

See More Headlines

Receive PNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 4/17/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PNT
CUSIP: N/A
CIK: 1811764
Web: www.pointbiopharma.com
Phone: 64-7812-2417
Fax: N/A
Employees: 129
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.80
High Stock Price Target: $14.00
Low Stock Price Target: $12.50
Potential Upside/Downside: +2.4%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.90
Trailing P/E Ratio: 13.89
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $98.29 million
Net Margins: 39.62%
Pretax Margin: 52.16%
Return on Equity: 21.10%
Return on Assets: 18.28%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 9.14
Quick Ratio: 9.14

Sales & Book Value

Annual Sales: $226.58 million
Price / Sales: 5.88
Cash Flow: $0.94 per share
Price / Cash Flow: 13.31
Book Value: $4.68 per share
Price / Book: 2.67

Miscellaneous

Outstanding Shares: 106,570,000
Free Float: 89,518,000
Market Cap: $1.33 billion
Optionable: Optionable
Beta: N/A

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Allan Charles Silber (Age 73)
Executive Chairman
Comp: $1.02M
Dr. Joe A. McCann Ph.D. (Age 45)
CEO & Director
Comp: $1.06M
Dr. Neil E. Fleshner FRCSC (Age 59)
M.D., M.PH, Chief Medical Officer & Director
Comp: $318.49k
Ms. Jessica D. Jensen M.P.H. (Age 43)
Executive Vice President of Clinical Development
Comp: $816.17k
Mr. Bill Demers B.B.A. (Age 64)
F.C.A., FCPA, CFO & Corporate Secretary
Comp: $78.26k
Ms. Justyna Kelly M.Sc. (Age 38)
Chief Operating Officer
Ms. Jazz Braich
SVP of People & Culture
Mr. Ari Shomair
VP of Corporate Affairs & Chief of Staff
Dr. Myra Rosario Herle Ph.D.
R.Ph., Executive Vice President of Regulatory Affairs
Dr. Matthew P. Vincent J.D.
Ph.D., Senior Vice President of Business Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PNT Stock Analysis - Frequently Asked Questions

Should I buy or sell POINT Biopharma Global stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PNT, but not buy additional shares or sell existing shares.
View PNT analyst ratings or view top-rated stocks.
What is POINT Biopharma Global's stock price target for 2024?: 10 analysts have issued 1-year price targets for POINT Biopharma Global's stock. Their PNT share price targets range from $12.50 to $14.00. On average, they anticipate the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 2.4% from the stock's current price.
View analysts price targets for PNT or view top-rated stocks among Wall Street analysts.
How were POINT Biopharma Global's earnings last quarter?: POINT Biopharma Global Inc. (NASDAQ:PNT) released its earnings results on Monday, November, 13th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.07. The business earned $2.79 million during the quarter, compared to analyst estimates of $8 million. POINT Biopharma Global had a trailing twelve-month return on equity of 21.10% and a net margin of 39.62%.

This page (NASDAQ:PNT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

POINT Biopharma Global (PNT) Stock Price, News & Analysis

POINT Biopharma Global MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

Company Ownership

Earnings and Valuation

About POINT Biopharma Global Stock (NASDAQ:PNT)

PNT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

PNT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™